XSHE
002100
Market cap1.55bUSD
Oct 09, Last price
7.68CNY
1D
0.79%
1Q
19.07%
Jan 2017
-14.38%
IPO
310.70%
Name
Tecon Biology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tecon Biology Co. Ltd. is a diversified agribusiness operating in China and globally, with key activities spanning animal nutrition, livestock, and financial services. The company's primary focus involves the research, development, manufacturing, and distribution of a comprehensive range of animal feed products, designed for various species including poultry, swine, ruminants, and aquatic life. Beyond specialized feeds, Tecon also produces essential protein feed components and edible oils sourced from soybeans, sunflowers, rapeseed, and cottonseeds. Its involvement in the livestock sector extends to pig breeding and rearing, as well as meat processing and sales. Additionally, the company is a producer and supplier of veterinary biological products. Expanding its portfolio, Tecon offers a variety of financial services, including loan and bill acceptance guarantees, trade and project financing, credit provisions, and supervision for commodity financing. Established in Urumqi, China, in 1993, the company adopted its current name, Tecon Biology Co.Ltd, in June 2016, having previously operated as Xinjiang Tecon Animal Husbandry Bio-Technology Co., Ltd.
Key people
Lixin Geng
Chief Financial Officer · since 2013
Hui Cheng
General Manager, Director
Qin Zhao
Deputy General Manager
Jiang Liu
Director · since 2013
Lijian Wang
Director · since 2006
Yan Yang
Chairman of the Board
Yiqun Zhou
Director · since 2010
Independent Director · since 2008
Yubin He
Independent Director · since 2009
Weihong Sun
Independent Director · since 2007
Xiong Yu
Independent Director · since 2008
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||